EFFECT OF ADDING BLOOD FLOW RESTRICTION TRAINING TO CLOSED CHAIN EXERCISE IN KNEE OSTEOARTHRITIS
NCT07917559, Not applicable, Not yet recruiting, Rasha Abdel Kader Abdel Azeem Khtab
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | EFFECT OF ADDING BLOOD FLOW RESTRICTION TRAINING TO CLOSED CHAIN EXERCISE IN KNEE OSTEOARTHRITIS | ClinicalTrials.gov |
| NCT number | NCT07917559 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Rasha Abdel Kader Abdel Azeem Khtab | ClinicalTrials.gov |
| Conditions | Knee Osteoarthritis | ClinicalTrials.gov |
| Interventions | Traditional and Closed Kinetic Chain Exercise Program | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Knee Pain Intensity Measured by the Numeric Pain Rating Scale (NPRS) | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Knee pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), an 11-point self-reported scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes from baseline will be assessed after treatment and at follow-up. | ClinicalTrials.gov |
| Primary | Change in Knee Range of Motion Measured by a Smartphone Digital Inclinometer | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Knee joint range of motion will be measured in degrees using a smartphone-based digital inclinometer application. Knee flexion and extension angles will be assessed to evaluate changes in joint mobility following the intervention. Changes from baseline will be evaluated at week 8 and week 12. | ClinicalTrials.gov |
| Primary | Change in Quadriceps Muscle Strength Measured by a Hand-Held Dynamometer | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Quadriceps muscle strength will be assessed using a hand-held dynamometer to measure isometric muscle force during voluntary contraction. The assessment will be performed using standardized testing procedures. Changes in quadriceps muscle strength from baseline will be evaluated after treatment and at follow-up. | ClinicalTrials.gov |
| Secondary | Change in Knee Function Measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Knee-related function will be assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS), a 42-item questionnaire covering five subscales: pain, symptoms, activities of daily living, sport and recreation, and knee-related quality of life. Each subscale is transformed to a score ranging from 0 to 100, with higher scores indicating better knee-related outcomes. | ClinicalTrials.gov |
| Secondary | Change in Functional Mobility Measured by the Timed Up and Go (TUG) Test | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants will be instructed to stand up from a chair, walk three meters, turn around, return to the chair, and sit down. The time required to complete the task will be recorded in seconds. Lower completion times indicate better functional mobility. | ClinicalTrials.gov |
| Secondary | Change in Health-Related Quality of Life Measured by the Short Form-36 (SF-36) | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Health-related quality of life will be assessed using the Short Form-36 (SF-36) questionnaire, which consists of 36 items evaluating physical and mental health domains. Scores range from 0 to 100, with higher scores indicating better health-related quality of life. Changes from baseline will be evaluated following treatment and at follow-up. | ClinicalTrials.gov |
| Secondary | Change in Patient Satisfaction Measured by the Patient Satisfaction Questionnaire (PSQ-18) | Baseline, week 8 (post-treatment), and week 12 (one-month follow-up). | Patient satisfaction with healthcare services will be assessed using the Patient Satisfaction Questionnaire Short Form (PSQ-18). The questionnaire contains 18 items covering seven dimensions: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with the healthcare provider, and accessibility and convenience. Items are rated using a five-point Likert scale. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)